Using a random-effects model, the pooled estimate demonstrated a significant relationship between PTEN loss and poorer OS (HR = 1.41, 95% CI = 1.08–1.73, P < 0.0001; Figure 5B), indicating that PTEN loss predicted worse prognosis in breast cancer patients. Here, PTEN is linked to breast carcinoma.